Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc.

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) is running a Phase 3 study testing romiplostim plus predni...

Amgen Targets First-Line ITP Market With New Phase 3 Romiplostim Trial

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Charles River Labs (CRL) and Amgen (AMGN) with bulli...

Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL) and Amgen (AMGN)

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. The phase 3 study A Phase 3 Randomized, Double-blind, Placebo-controlled Stu...

Amgen’s Phase 3 Dazodalibep Study Nears Data Spotlight for Sjögren’s Investors

The Schwab U.S. Dividend Equity ETF (SCHD) and the Vanguard Dividend Appreciation ETF (VIG) are two popular dividend ETFs, but they are built for d...

SCHD vs. VIG: Which Dividend ETF Has the Edge in 2026?

Analysts are intrested in these 5 stocks: ( ($PANW) ), ( ($ETN) ), ( ($AMGN) ), ( ($SPCX) ) and ( ($LMT) ). Here is a breakdown of their recent


Palo Alto, Eaton, Amgen, SpaceX, LMT Trending With Analysts

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) is launching a Phase 4 trial called “A Trial Assessing the...

Amgen’s New Repatha Plaque Trial: What Investors Should Watch

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Assembly Biosciences (ASMB), Waters (WAT) and Amge...

Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Waters (WAT) and Amgen (AMGN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Beam Therapeutics (BEAM) and Royalty...

Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Beam Therapeutics (BEAM) and Royalty Pharma (RPRX)

TD Cowen analyst Yaron Werber reiterated a Buy rating on Amgen today and set a price target of $452.00. Werber covers the Healthcare sector, focusi...

TD Cowen Keeps Their Buy Rating on Amgen (AMGN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (AMGN), Guardant Health (GH) and Neurocrine (N...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN) and NewAmsterdam Pharma Company (NAMS...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and NewAmsterdam Pharma Company (NAMS)

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen’s latest psoriasis study update spotlights apremilast (AMG 407) for ki...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AMGN	$414.61	+2.11%	2.21M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AMGN	$414.61	+2.1%	2.21M
3
4
5
6

AMGN

Get Amgen Inc. Data in Excel

Get Amgen Inc. Data in Excel